Demographic, mood, and drug treatment data from the control and Parkinson’s disease groups
| Variable | Controls | Parkinson’s disease |
|---|---|---|
| Data are mean (SEM). Proportions of groups manifesting a particular deficit are also given as (%). Where dichotomous responses do not equal 100%, this is because the remaining patients were unsure. | ||
| *χ2 test, p < 0.05. | ||
| PDI, peripheral decarboxylase inhibitor. | ||
| Age (years) | 74 (2) | 72 (1) |
| Parkinson’s disease duration (years) | – | 8.2 (1.0) |
| Hoehn and Yahr score | Score 0 (normal) | 1–1.5 (mild), n=5 |
| 2–3 (moderate), n=17 | ||
| 4–5 (end stage), n=8 | ||
| Drug treatment | ||
| Total daily L-dopa dosage (mg) | – | 592 (463) |
| Total daily PDI dosage (mg) | – | 126 (65) |
| Duration of L-dopa (years) | – | 7.1 (4.2) |
| Use of sedatives/hypnotics | 3/32 (9%) | 10/38 (26%)* |
| Anxiety | 5/32 (16%) | 19/38 (50%)* |
| Duration of anxiety (years) | 18.3 (14.4) | 4.9 (1.0) |
| Onset of anxiety relative to Parkinson’s disease (years) | – | 1.3 (1.2) |
| Improvement of anxiety after antiparkinsonian treatment? | – | Yes in 4/19 (11%); no in 14/19 (74%) |
| Depression | 2/32 (6%) | 6/38 (16%) |
| Duration of depression (years) | Unknown | 1.5 (1.3) |
| Onset depression relative to Parkinson’s disease (years) | – | 1.8 (0.9) |
| Improvement of depression after antiparkinsonian treatment? | – | Yes in 1/6 (17%); no in 4/6 (67%) |
| Excessive daytime sleepiness | 2/32 (6%) | 17/38 (45%)* |
| Duration of excessive daytime sleepiness (years) | ? | 3.6 (0.8) |
| Onset of excessive daytime sleepiness relative to Parkinson’s disease (years) | – | 4.5 (1.2) |
| Improvement in excessive daytime sleepiness after antiparkinsonian treatment? | – | Yes in 3/17 (18%); no in 14/17 (82%) |
| Restless legs | 6/32 (19%) | 19/38 (50%)* |
| Duration of restless legs (years) | 8.2 (4.7) | 2.7 (0.5) |
| Onset of restless legs relative to Parkinson’s disease (years) | – | 4.9 (1.1) |
| Improvement of restless legs after antiparkinsonian treatment? | – | Yes in 7/19 (37%); no in 11/19 (58%) |
| Disturbing or violent dreams | 1/32 (3%) | 4/38 (11%) |
| Duration of the dreams (years) | 2 | 4.2 (4.0) |
| Onset of dreams relative to Parkinson’s disease (years) | – | 3.0 (0.6) |
| Improvement of the dreams after antiparkinsonian treatment? | – | Yes in 0/4 (0%); no in 4/4 (100%) |
| Microsmia | 1/32 (3%) | 24/38 (68%)* |
| Duration of microsmia (years) | 7 | 6.7 (5.3) |
| Onset of microsmia relative to Parkinson’s disease (years) | – | 1.2 (1.5) |
| Improved microsmia after antiparkinsonian treatment? | – | Yes in 1/24 (4%); no in 23/24 (96%) |